24 results
P
24,913 participants
I/C
NA reduction, smoking relapse
O
weakly linked
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
adult
I/C
nucleoside analogues (NA), placebo or no intervention
O
virological cure, elimination of acute infection, mortality, and serious adverse events
P
women with ovarian cancer
I/C
metformin, statins, beta-blockers, aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs), users vs. non-users
O
ovarian cancer survival
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Hepatitis B virus (HBV) chronic infection patients
I/C
Nucleos(t)ide analogues (NA), plasma exchange, rituximab
O
suppression of HBV replication, clinical response, severe or life-threatening cases
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
IHCs
I/C
Pegylated interferon (Peg-IFN) treatment, Control group (including nucleos(t)ide analogue (NA) treatment or no treatment)
O
HBsAg clearance rate, conversion rate
P
765 participants
I/C
infiltrating nasal packing with local anesthetics, placebo packing
O
pain reduction, anxiety reduction
P
Individuals participating in blood flow restriction (BFR) training
I/C
BFR training, High-intensity resistance training (HIRT)
O
Muscular strength, hypertrophy, and endurance